

# **Reliability of Transient Elastography as a Non-Invasive Technique for Detection of Fibrosis in Budd Chiari syndrome Patients after Endovascular Intervention**

*Thesis*

*Submitted for Partial Fulfillment of MD Degree in Tropical Medicine*

*By*

**Ahmed Talaat Abd Elsamie Elganzory**

*Master degree of Tropical medicine*

*Faculty of Medicine - Ain Shams University*

*Under Supervision of*

**Prof. Mohamed Fawzy Montasser**

*Former Dean of Faculty of Medicine-Ain Shams University*

*Professor of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

**Prof. Eman Mahmoud Fathy Barakat**

*Professor of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

**Prof. Mohamed Shaker Ghazy**

*Professor of Radiodiagnosis and Interventional Radiology*

*Faculty of Medicine - Ain Shams University*

**Prof. Sara Mahmoud Abdelhakam**

*Professor of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

**Dr. Hend Elsaid Ebada**

*Lecturer of Tropical Medicine*

*Faculty of Medicine - Ain Shams University*

*Faculty of Medicine*

*Ain Shams University*

*2020*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

First and forever, thanks to **Allah**, Almighty for giving me the strength and faith to complete my thesis and for everything else

I would like to express my deepest gratitude and great respect to **Prof. Mohamed Fawzy Montasser**, Professor of Tropical Medicine, under his supervision I had the honor and pleasure to proceed with work. His constant guidance, encouragement and foresight made all the difference.

I would like to express my deepest thanks to **Prof. Eman Mahmoud Fathy Barakat** Professor of Tropical Medicine, for her continuous guidance and encouragement.

My deepest appreciation goes to **Prof. Sara Mahmoud Abdelhakam**, professor of Tropical Medicine, for her valuable suggestions, advice, efforts, creativity and offering me her precious time.

Special thanks go to **Dr. Hend Elsaid Ebada** lecturer of tropical medicine, for her help, co-operation, active participation and guidance.

I would like to express my deepest thanks to **Prof. Mohamed Shaker Ghazy** Professor of Radiodiagnosis and Interventional Radiology for his help, co-operation, active participation and guidance.

I would like to express my hearty thanks to all **my family** for their support till this work was completed.

Last but not least, my sincere thanks and appreciation to all patients participated in this study.

**Ahmed Talaat Elganzory**

# *List of Contents*

Title	Page No.
List of Tables .....	5
List of Figures .....	7
List of Abbreviations .....	8
Introduction .....	1
Aim of the Work .....	6
Review of Literature	
Budd-Chiari Syndrome.....	7
Tools for Assessment of Liver Fibrosis .....	45
Patients and Methods .....	77
Results .....	86
Discussion .....	100
Summary .....	114
Conclusion.....	119
Recommendations .....	120
References .....	121
Arabic Summary .....	—

# *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Etiology of BCS .....	10
<b>Table (2):</b>	The international criteria for behcet disease .....	28
<b>Table (3):</b>	Approximate prevalence of major risk factors in patients with primary BCS.....	32
<b>Table (4):</b>	Relative risks and comparison of common thrombophilic conditions. ....	33
<b>Table (5):</b>	Ranges of CAP scores and the matching steatosis grade and amount of fatty change.....	72
<b>Table (6):</b>	Demographic and clinical data of the involved patients ..	86
<b>Table (7):</b>	Laboratory data of the involved patients .....	87
<b>Table (8):</b>	Causes of thrombophilia the involved patients .....	88
<b>Table (9):</b>	Radiological data of the involved patients.....	89
<b>Table (10):</b>	Type of radiological intervention.....	90
<b>Table (11):</b>	Radiological investigations for follow up of the patients.....	91
<b>Table (12):</b>	Clinical data before and after intervention .....	92
<b>Table (13):</b>	Laboratory investigations before and after intervention ..	92
<b>Table (14):</b>	Abdominal US with duplex study before and after intervention .....	93
<b>Table (15):</b>	Correlation between LSM and HVPG before intervention. ....	94
<b>Table (16):</b>	Correlation between LSM three months post-intervention and HVPG immediately post-intervention...	95
<b>Table (17):</b>	Comparison between LSM pre-intervention and post-intervention. ....	96
<b>Table (18):</b>	Comparison between HVPG pre-intervention and post-intervention. ....	97

## *List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (19):</b>	Relation between LSM before and after intervention and METAVIR Score:.....	98
<b>Table (20):</b>	Comparison between LSM before and after intervention with Metavir score .....	99

## *List of Figures*

Fig. No.	Title	Page No.
Figure (1):	function of ATIII .....	15
Figure (2):	Causes of Hyperhomocysteinemia .....	17
Figure (3):	Proposed algorithm for a diagnosis of myeloproliferative disease (MPD) in patients with primary BCS.....	24
Figure (4):	Correlation between LSM and HVPG before intervention .....	94
Figure (5):	Correlation between LSM and HVPG after intervention. ....	95
Figure (6):	LSM pre and post intervention. ....	96
Figure (7):	HVPG pre- and post- intervention .....	97

# *List of Abbreviations*

Abb.	Full term
AAR.....	The AST/ALT ratio
ACAs.....	Anticardiolipin Antibodies
ACL IgG.....	Anticardiolipin IgG
ACL IgM .....	Anticardiolipin IgM
AIH .....	Autoimmune hepatitis
ALB.....	Albumin
ALP .....	Alkaline phosphatase
ALT.....	Alanin amino-transferase
AMM.....	Agnogenic myeloid metaplasia
ANA .....	Anti nuclear antibody
Anti DNA .....	Anti double stranded DNA
Anti-beta-2GPI...	Anti-beta 2 glycoprotein I
AP .....	The age/platelet index
APAs .....	Antiphospholipid antibodies
APC.....	Activated protein C
APCR .....	Activated protein C resistance
APLAS .....	Antiphospholipid antibody syndrome
APRI .....	The Aspartate Aminotransferase to Platelet Ratio Index
APS .....	Antiphospholipid syndrome
APTT.....	Activated partial thromboplastin time
ARFI .....	Acoustic Radiation Force Impulse Elastography
AST.....	Aspartate amino-transferase
AT III.....	Antithrombin III
BCS.....	Budd-Chiari syndrome
BD.....	Behcet Disease
BM .....	Bone marrow
BMI.....	Body mass index



## *List of Abbreviations Cont...*

Abb.	Full term
BS .....	Bonacini's discriminant score
BUN.....	Blood urea nitrogen
CAP.....	Controlled attenuation parameter
CHB.....	Chronic hepatitis B
CHC.....	Chronic hepatitis C
CLD.....	Chronic liver disease
CML.....	Chronic Myeloid leukemia
CT .....	Computed Tomography
DIC .....	Disseminated intravascular coagulation
EASL.....	European Association for the Study of the Liver
ECM.....	extracellular matrix
EEC.....	endogenous erythroid colony
EFSUMB.....	European Federation of Societies for Ultrasound in Medicine and Biology
ELF.....	Enhanced liver fibrosis
ESR.....	Erythrocyte sedimentation rate
ET .....	Essential thrombocythemia
FAB.....	French-American-British
FDA.....	Federal Drug Administration
FISH .....	Fluorescent in-situ hybridization
FV .....	Factor V
FVa .....	Activated factor V
FVLM.....	Factor V Leiden mutation
HA.....	Hyaluronic acid
Hb .....	Hemoglobin
HCC .....	Hepatocellular carcinoma
HcT .....	Hematocrit
Hetero .....	Heterozygous

## *List of Abbreviations Cont...*

Abb.	Full term
HH .....	Hyperhomocysteinemia
Homo.....	Homozygous
INR .....	International normalized ratio
IQR .....	interquartile range
IVC.....	Inferior vena cava
JAK <sub>2</sub> .....	Janus tyrosine kinase-2
kPa.....	Kilopascal
LAC.....	Lupus Anticoagulant
LAP .....	Leukocyte alkaline phosphatase
LSM .....	liver stiffness measurements
LSN.....	liver surface nodularity
MF .....	Myelofibrosis
MMP/ TIMP .....	metallo-proteinase/ tissue inhibitor of metalloproteinase
MOVC .....	membranous obstruction of the IVC
MPDs .....	Myeloproliferative disorders
MRE.....	Magnetic resonance elastography
MRI.....	Magnetic resonance imaging
MTHFR.....	Methylenetetrahydro-folate reductase
NAD .....	No abnormality detected
NAFLD.....	Non alcoholic fatty liver disease
NASH.....	Non alcoholic steatohepatitis
OCPs.....	Oral Contraceptive Pills
OLT.....	orthotopic liver transplantation
PC .....	Protein C
PCR.....	Polymerase chain reaction
PGM.....	Prothrombin gene mutation
PICP.....	Procollagen type carboxy terminal peptide
PIIINP .....	Procollagen type III amino terminal peptide

## *List of Abbreviations Cont...*

Abb.	Full term
PLT .....	Platelets
PNH.....	Paroxysmal nocturnal hemoglobinuria
PS .....	Protein S
PT .....	Prothrombin time
PTFE.....	Polytetrafluoroethylene
PTT .....	Partial thromboplastin time
PV .....	Polycythemia vera
PV .....	Portal vein
PVT.....	Portal vein thrombosis
SAAG .....	Serum-ascites albumin gradient
SD .....	Standard deviation
SLE.....	Systemic lupus erythematosus
SWE.....	Shear Wave Elastography
TB .....	Total bilirubin
TE .....	Transient Elastography
TGF- $\beta$ .....	tumor growth factor $\beta$
TIPS.....	Transjugular Intrahepatic Portosystemic Shunt
WBCs .....	White blood cells
WHO .....	World Health Organization
$\beta$ 2 GPI.....	$\beta$ 2-glycoproteine I

# INTRODUCTION

**B**udd–Chiari (BCS) syndrome is a heterogeneous group of disorders characterized by hepatic venous outflow obstruction at the level of the hepatic venules, the large hepatic veins, the inferior vena cava till its junction with the right atrium (*Valla, 2008*).

BCS is further classified as being primary or secondary, depending on the exact nature of the hepatic venous outflow obstruction. When flow is obstructed by compression or invasion of a lesion outside the hepatic venous outflow track, it is regarded as being secondary BCS; examples include malignant and cystic extrinsic obstruction. If flow is obstructed due to an end luminal aberration, then it is classified as being primary BCS (*DeLeve et al., 2009*).

Hepatic venous outflow obstruction causes centrilobular congestion and hepatocyte necrosis, which if not treated can lead to hepatic lobulation and cirrhosis. The evolution and severity of these changes vary widely and depend upon the cause, degree and extent of obstruction. Thus, the clinical presentation of BCS has a wide spectrum and ranges from asymptomatic cases to fulminant hepatic failure (*Darwish et al., 2009*).

The classic triad of abdominal pain, ascites, and hepatomegaly is observed in the vast majority of patients with

Budd-Chiari syndrome, but it is nonspecific. A high index of suspicion is needed to make the diagnosis. Patients with acute onset of obstruction typically present with acute right upper quadrant pain. Abdominal distention can also be a significant symptom, because of ascites. Jaundice is rarely observed (*Goel et al., 2015*).

The goals of treatment are to prevent extension of thrombosis in the hepatic veins and to alleviate venous obstruction in order to decrease hepatic congestion. Few patients respond to medical treatment (anticoagulation with or without thrombolytic therapy, diuretics). However, most of patients need more invasive procedures to restore the hepatic blood flow including percutaneous angioplasty with or without stenting, transjugular intrahepatic portosystemic shunt (TIPS) or shunt surgery (*Pieter and Frederik, 2015*).

Liver fibrosis is the single most important factor determining the prognosis in CLD. Detection of earlier stages of liver fibrosis may be helpful in prevention of its progression and may even result in complete regression if appropriate treatment is instituted (*Fowell and Iredale, 2006*).

Fibrosis is a dynamic process and many studies have suggested that liver fibrosis is actually reversible when the underlying condition is treated. In the early stages of fibrosis, it may be possible to achieve a total curative effect. Therefore,

the early diagnosis and prevention of liver fibrosis is of great importance in the clinical setting (*Shin et al., 2016*).

Patients with advanced fibrosis and cirrhosis are generally recommended to undergo clinical surveillance for complications (*Lok et al., 2009*). Staging of liver fibrosis is therefore important in the management of CLD.

The presence and degree of hepatic fibrosis is crucial in order to make therapeutic decisions and predict clinical outcomes. Currently, the place of liver biopsy as the standard of reference for assessing liver fibrosis has been challenged by the increasing awareness of a number of drawbacks related to its use (invasiveness, sampling error, inter-/intraobserver variability). In parallel with this, noninvasive assessment of liver fibrosis has experienced explosive growth in recent years and a wide spectrum of noninvasive methods ranging from serum assays to imaging techniques have been developed. Some are validated methods, such as the Fibrotest and transient elastography, and are gaining a growing role in routine clinical practice, especially in chronic hepatitis C. Large-scale validation is awaited in the setting of other chronic liver diseases. However, noninvasive tests used to detect significant fibrosis and cirrhosis, the two major clinical endpoints, are not yet at a level of performance suitable for routine diagnostic tests, and there is still no perfect surrogate or method able to completely replace an optimal liver biopsy (*Vasilios et al., 2012*).

Transient Elastography is a shear wave and ultrasound-based method, developed by Echosens® (France), initiated from the principles of Hooke's law, which characterizes a material's strain response to external stress (*Arinc et al., 2018*).

The evaluation of the effectiveness of BCS treatment is generally based on symptoms, which inevitably introduces subjective factors and errors (*Valla , 2009*). Although Doppler ultrasound has unique advantages as a preferred test for BCS, it has certain technical limitations when used in follow-up examination. Doppler ultrasound may be affected by imaging depth and angle; it has less value in patients with porous and/or membranous lesions of the IVC, and is operator dependent). Moreover, for lesions with less significant hemodynamic changes, Doppler ultrasound lacks sensitivity in evaluating short- and long-term outcomes after therapy (*Boozari et al., 2008*).

Though unrelated to the degree of liver fibrosis, LSM is highly sensitive to the changes in hepatic venous pressure. Therefore, efficacy of treatment based on SWE can not only improve the outcome evaluation, but also reduce invasiveness (*Wang et al., 2018*).

Liver stiffness (LS) measurements made with FibroScan Transient Elastography(TE) can be used as a noninvasive tool to assess hepatic congestion and there by indirectly provide insights into the technical outcome and the benefits of endo-